$德納維製藥 (DVAX.US)$ Dynavax Technologies Down Over 7%, On Track for Largest Percent Decrease Since August 2022 -- Data Talk Dow Jones· 2 mins ago2mins Dynavax Technologies Corporation ( DVAX ) is currently at $12.42, down $0.97 or 7.21% --Would be lowest close since Nov. 7, 2024, when it closed at $12.02 --On pace for largest percent decrease since Aug. 17, 2022, when it fell 10.39% --Currently down three of the past four days --Currently down two consecutive days; down 8.1% ov...
$德納維製藥 (DVAX.US)$ Dynavax Announces $200 Million Share Repurchase Program Dynavax (DVAX) reported strong Q3 2024 financial results, with HEPLISAV-Bachieving record quarterly net product revenue of $79.3 million, up 27% year-over-year. The company's total revenues reached $80.6 million, a 16% increase from Q3 2023. HEPLISAV-B's U.S. market share grew to 44%, with particularly strong performance in retail pharmacy (55%) and IDN segments (56%). The company expects the hepatitis B...
$德納維製藥 (DVAX.US)$Reuters· 1 min ago Dynavax: Crl States Application Did Not Provide Sufficient Data to Support Full Evaluation of Effectiveness or Safety of 4-Dose Regimen of Heplisav-B
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date. $輝瑞 (PFE.US)$$德納維製藥 (DVAX.US)$$沙塵暴黃金 (SAND.US)$$施貴寶 (BMY.US)$$SPDR標普生物科技ETF (XBI.US)$
Dynavax Technologies' long-term performance remains strong despite a recent 8.6% pullback. The company's profit growth is commendable, and its 15% annual gain, though below market return, surpasses its 5-year average, suggesting a successful strategy attracting new investors.
📈 Stock #1 - SoFi 📈 Dr. Stock is bullish on SoFi, considering it a fundamental long-term play with potential growth. He's eagerly awaiting Q2 earnings to see if they stay on track to achieve profitability by Q4 2023. Dr. Stock talks about possible price drops in the short term, which could create great buying opportunities for the long term. He also discusses potential resistance levels and trade plays as the stock approaches key price points. 🚗 Stock #2 - Tes...
Welcome back to the channel! In this video, Dr. Stock, a doctor of Education, will be discussing various stocks, including some he recently mentioned in his previous videos. He provides updates on Sofi and Tesla as well. Dr. Stock focuses on stocks that are currently not hyped up, which makes their technical analysis more predictable compared to heavily hyped stocks like pure play A.I. stocks. To analyze these stocks, Dr. Stock uses Moomoo, a platform where you can get up...
德納維製藥股票討論
Dynavax Technologies Down Over 7%, On Track for Largest Percent Decrease Since August 2022 -- Data Talk
Dow Jones· 2 mins ago2mins
Dynavax Technologies Corporation ( DVAX ) is currently at $12.42, down $0.97 or 7.21%
--Would be lowest close since Nov. 7, 2024, when it closed at $12.02
--On pace for largest percent decrease since Aug. 17, 2022, when it fell 10.39%
--Currently down three of the past four days
--Currently down two consecutive days; down 8.1% ov...
Dynavax Announces $200 Million Share Repurchase Program
Dynavax (DVAX) reported strong Q3 2024 financial results, with HEPLISAV-Bachieving record quarterly net product revenue of $79.3 million, up 27% year-over-year. The company's total revenues reached $80.6 million, a 16% increase from Q3 2023. HEPLISAV-B's U.S. market share grew to 44%, with particularly strong performance in retail pharmacy (55%) and IDN segments (56%). The company expects the hepatitis B...
🗓️ Last week’s PDUFAs:
$安進 (AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$施貴寶 (BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$德納維製藥 (DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S (ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...
Dynavax: Crl States Application Did Not Provide Sufficient Data to Support Full Evaluation of Effectiveness or Safety of 4-Dose Regimen of Heplisav-B
📣 4 PDUFAs upcoming in May:
$德納維製藥 (DVAX.US)$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S (ASND.US)$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$施貴寶 (BMY.US)$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4製藥 (XFOR.US)$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
$輝瑞 (PFE.US)$ $德納維製藥 (DVAX.US)$ $沙塵暴黃金 (SAND.US)$ $施貴寶 (BMY.US)$ $SPDR標普生物科技ETF (XBI.US)$
Dr. Stock is bullish on SoFi, considering it a fundamental long-term play with potential growth. He's eagerly awaiting Q2 earnings to see if they stay on track to achieve profitability by Q4 2023. Dr. Stock talks about possible price drops in the short term, which could create great buying opportunities for the long term. He also discusses potential resistance levels and trade plays as the stock approaches key price points.
🚗 Stock #2 - Tes...
To analyze these stocks, Dr. Stock uses Moomoo, a platform where you can get up...
暫無評論